1167415-61-3

Upstream product

• 175714-94-0 1,1-dimethylethyl 7-[(hydroxyamino)(imino)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 1072948-37-8 3-cyano-4-[(1-methylethyl)oxy]benzoyl chloride 
• 264264-28-0 1,1-dimethylethyl-7-{[(trifluoromethyl)sulfonyl]oxy}-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 149354-02-9 1,1-dimethylethyl 7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 1167416-30-9 1,1-dimethylethyl 7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 

Downstream Products

• 1167416-38-7 ethyl 4-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]butanoate 
• 1167416-39-8 ethyl 4-(7-{5-[4-[(1-methylethyl)oxy]-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)butanoate 
• 1258852-21-9 2-[(1-methylethyl)oxy]-5-(3-{3-[2-(methyloxy)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-1,2,4-oxadiazol-5-yl)benzonitrile 
• 1258852-22-0 3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]propanamide 
• 1258852-23-1 3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-N,N-dimethylpropanamide 
• 1258856-62-0 1,1-dimethylethyl [7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-l,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetate 
• 1258855-48-9 1,1-dimethylethyl {2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-oxoethyl}carbamate 
• 1258855-72-9 methyl [7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetate 
• 1258856-42-6 methyl (2R)-3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-hydroxypropanoate 
• 1258853-00-7 5-(3-{3-[(2R)-2,3-dihydroxypropyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile 
• 1258852-27-5 5-{3-[3-(2,3-dihydroxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile 
• 1258855-80-9 5-{3-[3-(bromoacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile 
• 1258856-09-5 1,1-dimethylethyl {2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydo-3H-3-benzazepin-3-yl]-1,1-dimethyl-2-oxoethyl}carbamate 
• 1258852-19-5 5-{3-[3-(2-hydroxyethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile 

Relevant academic research and scientific papers

Discovery of a brain-penetrant S1P3-sparing direct agonist of the S1P1 and S1P5 receptors efficacious at low oral dose

2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on

S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING

The present invention relates to novel compounds of formula (I) having S1P1 agonist activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)

The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two substituent